GlassScriptPhysician profile
Agustin Andrade
NPI 1104869064
$30,052.95
in general payments reported to CMS, 2019-2025
33 companies · $9,150 in 2025
The $9,150 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,153 · 2020: $2,143 · 2021: $932 · 2022: $646 · 2023: $7,836 · 2024: $6,193 · 2025: $9,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,313 · Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $18,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,312.50 |
| Food and Beverage | $865.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cambridge Interventional LLC | $19,356.14 | 2023-2025 | Crf |
| Abbvie INC. | $3,687.26 | 2019-2025 | Synthroid |
| Sanofi-Aventis U.S. LLC | $1,014.70 | 2019-2022 | |
| Lilly USA, LLC | $883.04 | 2019-2023 | Retevmo, Lyumjev, Baqsimi |
| Novo Nordisk INC | $826.98 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $633.48 | 2019-2021 | |
| Ibsa Pharma INC. | $439.60 | 2019-2025 | Tirosint, Tirosint, Licart |
| Currax Pharmaceuticals LLC | $387.61 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $356.35 | 2019-2025 | Unithroid |
| Horizon Therapeutics Plc | $259.96 | 2019-2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $222.13 | 2019 | |
| Mannkind Corporation | $207.27 | 2019-2021 | |
| Shire North American Group INC | $180.79 | 2019 | |
| Radius Health, INC. | $177.89 | 2019-2023 | |
| Insulet Corporation | $177.62 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.27 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $162.88 | 2023-2024 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $113.70 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $106.63 | 2019 | |
| Corcept Therapeutics | $100.90 | 2020-2022 | |
| Exelixis INC. | $87.32 | 2023 | Cabometyx |
| Janssen Pharmaceuticals, INC | $66.25 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $62.94 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $59.46 | 2019-2021 | |
| Amgen INC. | $53.98 | 2019-2025 | Tepezza |
| Senseonics, Incorporated | $45.00 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $43.28 | 2019 | |
| Valeritas, INC. | $42.38 | 2019 | |
| Amryt Pharma Holdings LTD | $39.69 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $24.95 | 2019 | |
| Pfizer INC. | $22.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.90 | 2020 | |
| Endo Pharmaceuticals INC. | $19.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agustin Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.